Vanadium complex: an appropriate candidate for killing hepatocellular carcinoma cancerous cells

Hepatocellular carcinoma (HCC) is a prevalent human malignancy which its drug resistance is increasing world-wide. This project was designed to assess the anti-cancer effects of 4-bromo-2-(((5-chloro-2-hydroxyphenyl) imino) methyl) phenol ([IV(L)] complex) on the HepG2 cell line and also L929 cells,...

Full description

Saved in:
Bibliographic Details
Published in:Biometals 2018-12, Vol.31 (6), p.981-990
Main Authors: Bakhshi Aliabad, Hamid, Khanamani Falahati-pour, Soudeh, Ahmadirad, Hadis, Mohamadi, Maryam, Hajizadeh, Mohammad Reza, Mahmoodi, Mehdi
Format: Article
Language:English
Subjects:
Animals
Annexin V
Anticancer properties
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Apoptosis
Biochemistry
Biomedical and Life Sciences
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - pathology
Cell Biology
Cell culture
Cell Death - drug effects
Cell Proliferation - drug effects
Dose-Response Relationship, Drug
Drug resistance
Drug Screening Assays, Antitumor
Gangrene
Hep G2 Cells
Hepatocellular carcinoma
Hepatocytes
Humans
Life Sciences
Liver
Liver cancer
Liver Neoplasms - drug therapy
Liver Neoplasms - pathology
Malignancy
Medicine/Public Health
Mice
Microbiology
Necrosis
Organometallic Compounds - chemical synthesis
Organometallic Compounds - chemistry
Organometallic Compounds - pharmacology
Pharmacology/Toxicology
Phenols
Plant Physiology
Side effects
Structure-Activity Relationship
Survival
Vanadium
Vanadium - chemistry
Vanadium - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is a prevalent human malignancy which its drug resistance is increasing world-wide. This project was designed to assess the anti-cancer effects of 4-bromo-2-(((5-chloro-2-hydroxyphenyl) imino) methyl) phenol ([IV(L)] complex) on the HepG2 cell line and also L929 cells, as normal cells. HepG2 and L929 cells were cultured in RPMI culture medium and the survival rates of the cells were determined after 24 and 48 h using MTT assay to find IC50 concentration of vanadium m, [IV(L)] complex. The early apoptosis and necrosis/late apoptosis were determined by means of annexin V/PI apoptosis detection kit. The results revealed that vanadium m, [IV(L)] complex induce early apoptosis higher in HepG2 cell line than L929 cells. The rates of necrosis/late apoptosis were also induced in HepG2 cells more than L929 cells. Based on the results, vanadium m, [IV(L)] complex might be considered as a safe new drug for treatment of HCC with low side effects on control liver cells.
ISSN:0966-0844
1572-8773
DOI:10.1007/s10534-018-0139-x